BioSpace News Archive

A recently announced report titled Global Allergy Treatment Market Size, Share, Growth, Industry Trends and Forecast 2029 by Data Bridge Market Research aims to deliver a detailed investigation of all necessary data related to the global market.

Teleradiology Market study by “Data Bridge Market Research” provides details about the market dynamics affecting the Teleradiology market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

Rehabilitation Equipment Market study by “Data Bridge Market Research” provides details about the market dynamics affecting the Rehabilitation Equipment market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

Nicotine Replacement Therapy Market study by “Data Bridge Market Research” provides details about the market dynamics affecting the Nicotine Replacement Therapy market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

Digital Stethoscope Market study by “Data Bridge Market Research” provides details about the market dynamics affecting the Digital Stethoscope market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

The “Alzheimer’s Disease Treatment Market Growth (Status and Outlook) 2022-2029” Study has been added to Data Bridge Market Research’s repository.

DBMR added a comprehensive research document of 350+ pages on ‘Global Augmented Reality (AR) and Virtual Reality (VR) in Healthcare Market Share, Size, Industry Trends and Forecast 2028 with detailed insights on growth factors and strategies.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to provide an update on its ADC programs in development using Defence’s AccumTM, including key in vivo studies with worldwide collaborators.

BioHarvest Sciences Inc. (CSE: BHSC) (OTC PINK: CNVCF) (FSE: 8MV) (“BioHarvest” or “the Company”) today announced Q2 2022 sales orders of its flagship VINIA® product reached a record high of USD 947k, representing 99% growth compared to the same quarter of last year and 24% growth compared to Q1 2022.

PharmaJet®, a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, announced that their latest research results were presented at the BIO International Convention in June.